The combination of Roche’s Tecentriq (atezolizumab) and Exelixis’ Cabometyx (cabozantinib) met one of the primary endpoints in the pivotal Phase III CONTACT-02 trial, significantly improving progression-free survival in patients with metastatic castration-resistant prostate cancer, according to interim data released Monday by the companies.
Tag Archive for: Cabometyx
Data from the Phase III CONTACT-03 study showed the combination of Roche’s Tecentriq (atezolizumab) and Exelixis’ Cabometyx (cabozantinib) fell short of its primary endpoint of progression-free survival in renal cell carcinoma (RCC).
Exelixis’ cancer portfolio stumbled Thursday as the Alameda, CA-based company reported that a Phase III study of cabozantinib in combination with Roche’s Tecentriq (atezolizumab) failed to hit the primary endpoint of overall survival in second-line non-small cell lung cancer.
